You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer

 

Online download statistics by month:

Online download statistics by month: November 2023 to July 2025

AbstractFullPdf
Nov 2023280018
Dec 20239809
Jan 202411507
Feb 20248405
Mar 2024176012
Apr 202411001
May 202484013
Jun 20247908
Jul 20247605
Aug 20247107
Sep 20246807
Oct 20246808
Nov 20246708
Dec 20242807
Jan 20252804
Feb 20251008
Mar 2025003
Apr 2025105
May 2025108
Jun 2025103
Jul 2025001
Total14450147